Gross Profit Margin (Quarterly) Chart

Historical Gross Profit Margin (Quarterly) Data

View and export this data back to 2002. Start Trial.
Date Value
June 30, 2026 42.70%
March 31, 2026 44.82%
December 31, 2025 53.63%
September 30, 2025 54.67%
June 30, 2025 53.62%
March 31, 2025 55.56%
December 31, 2024 57.68%
September 30, 2024 56.86%
June 30, 2024 57.64%
March 31, 2024 58.57%
December 31, 2023 55.60%
September 30, 2023 56.35%
June 30, 2023 55.79%
March 31, 2023 57.17%
December 31, 2022 56.74%
September 30, 2022 59.07%
June 30, 2022 46.76%
March 31, 2022 52.87%
December 31, 2021 50.85%
September 30, 2021 53.42%
June 30, 2021 49.08%
March 31, 2021 53.67%
December 31, 2020 50.37%
September 30, 2020 50.42%
June 30, 2020 52.40%
Date Value
March 31, 2020 51.46%
December 31, 2019 50.75%
September 30, 2019 54.20%
June 30, 2019 47.99%
March 31, 2019 52.42%
December 31, 2018 50.16%
September 30, 2018 51.48%
June 30, 2018 52.22%
March 31, 2018 53.45%
December 31, 2017 52.87%
September 30, 2017 49.73%
June 30, 2017 51.56%
March 31, 2017 47.68%
December 31, 2016 55.50%
September 30, 2016 52.34%
June 30, 2016 52.28%
March 31, 2016 56.64%
December 31, 2015 57.20%
September 30, 2015 59.19%
June 30, 2015 59.15%
March 31, 2015 53.02%
December 31, 2014 56.66%
September 30, 2014 56.97%
June 30, 2014 57.68%
March 31, 2014 55.37%

Gross Profit Margin Definition

Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.

Read full definition.

Gross Profit Margin (Quarterly) Range, Past 5 Years

View Gross Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Gross Profit Margin (Quarterly) Benchmarks

View Gross Profit Margin (Quarterly) Benchmarks
Start Trial
Takeda Pharmaceutical Co., Ltd. 57.57%
Teva Pharmaceutical Industries Ltd. 52.07%
Novo Nordisk A/S 78.21%
AstraZeneca PLC 76.09%
ANI Pharmaceuticals, Inc. 54.97%